8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 17, 2014

QUIDEL CORPORATION

(Exact name of Registrant as specified in its Charter)

Delaware (State or Other Jurisdiction of Incorporation)	0-10961 (Commission File Number)	94-2573850 (IRS Employer Identification No.)
12544 High Bluff Drive, Suite 200 San Diego, California (Address of Principal Executive Offices)		92130 (Zip Code)
Registrant's telephone number, including area code: (858) 552-1100
	Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 17, 2014, the Board of Directors of Quidel Corporation (the “Company”) increased the size of the Company’s Board of Directors from seven to eight members pursuant to the Company’s Bylaws and appointed Kenneth J. Widder, M.D. to the Board effective as of November 17, 2014 to fill the vacancy. Dr. Widder has not yet been appointed to serve on any Board committees, although in the future he may be appointed to serve on one or more committees.

As a non-employee director, Dr. Widder will be compensated on the same basis as all other non-employee directors of the Company. Accordingly, Dr. Widder will receive a pro rata portion of a $40,150 annual retainer for his service on the Board and upon his appointment received an initial grant of 157 time-based restricted stock units and 3,333 non-qualified stock options, which reflects a pro rata portion of the annual grants made to non-employee directors in 2014 under the Company’s Amended and Restated 2010 Equity Incentive Plan.

There is no arrangement or understanding between Dr. Widder and any other person pursuant to which he was selected as a director. Dr. Widder has entered into the standard Company director indemnification agreement.

The Company issued a press release announcing the appointment of Dr. Widder on November 18, 2014. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K.

Item 9.01    Financial Statements and Exhibits.

The following exhibit is furnished with this current report on Form 8-K:
Exhibit Number	Description of Exhibit
99.1	Press release, dated November 18, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 19, 2014

QUIDEL CORPORATION
By:	/s/ Robert J. Bujarski
Name:	Robert J. Bujarski
Its:	SVP, Business Development & General Counsel

EXHIBIT INDEX

Exhibit Number	Description of Exhibit
99.1	Press release, dated November 18, 2014.

EX-99.1

Quidel Contact:	Media and Investors Contact:
Quidel Corporation	Quidel Corporation
Randy Steward	Ruben Argueta
Chief Financial Officer	858.646.8023
858.552.7931	ruben.argueta@quidel.com

Dr. Kenneth J. Widder Joins Quidel’s Board of Directors

SAN DIEGO, CA - (Marketwired) - November 18, 2014 - Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Kenneth J. Widder, M.D. has agreed to join Quidel’s Board of Directors, effective immediately. Quidel’s Board has been expanded to eight members.

Dr. Widder has more than thirty years of experience working with biomedical companies and has been a General Partner with Latterell Venture Partners since 2007. Dr. Widder is also a member of the Board of Directors of Evoke Pharma Inc., Meritage Pharma Inc., and Naurex Inc. He holds an M.D. from Northwestern University and trained in pathology at Duke University.

“We are fortunate to have Ken Widder join our Board. He has extensive expertise in launching new products, understands the diagnostic industry, and has experience with multiple publicly-traded and privately-held companies. We are delighted that Dr. Widder has agreed to serve on the Board of Quidel,” said Mark A. Pulido, Chairman of the Board.

About Quidel Corporation

Quidel Corporation serves to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the QuickVue^®, D3^® Direct Detection and Thyretain ^® leading brand names, as well as under the new Sofia^®, AmpliVue^® and Lyra™ brands, Quidel’s products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, influenza, respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease andfecal occult blood. Quidel’s research and development engine is also developing a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality of healthcare in physicians’ offices and hospital and reference laboratories. For more information about Quidel’s comprehensive product portfolio, visit quidel.com.